Company Encyclopedia
View More
name
Sinobioway Medicine
002581.SZ
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon a2b injection; Jiefu, a human interferon a2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine.
3.165 T
002581.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking198/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-11.15%D
    • Profit Margin-85.65%E
    • Gross Margin22.23%D
  • Growth ScoreD
    • Revenue YoY-36.54%E
    • Net Profit YoY36.48%B
    • Total Assets YoY-3.54%D
    • Net Assets YoY-9.61%D
  • Cash ScoreE
    • Cash Flow Margin-116.76%D
    • OCF YoY-36.54%E
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio10.00%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The flu vaccine has a "freezing point price" of 5.5 yuan

    In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that "the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the winning announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing being awarded the "immunization" project. (Yicai)

    36Kr·
    SZ
    002007
    -0.19%
    SZ
    002581
    +1.89%
    36Kr·
    SZ
    002007
    -0.19%
    SZ
    002581
    +1.89%

    Sinobioway Medicine: Net loss of 67.3027 million yuan in the first half of 2025

    ST Sinobioway Medicine announced that in the first half of 2025, operating revenue was 70.7715 million yuan, a year-on-year decrease of 66.42%. The net loss attributable to shareholders of the listed company was 67.3027 million yuan, compared to a net loss of 29.6149 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves

    Zhitong·
    SZ
    002581
    +1.89%
    Zhitong·
    SZ
    002581
    +1.89%

    Sinovac's combined hepatitis A and B vaccine, Beirlaifu, is re-registered for market launch

    Beijing Kexing Holdings Co., Ltd. subsidiary Beijing Kexing Biological Products Co., Ltd. independently developed the combined hepatitis A and B vaccine Beirlaifu, which has obtained the drug re-registration approval notice, making it the only combined hepatitis A and B vaccine approved for market in China

    Zhitong·
    SZ
    002581
    +1.89%
    Zhitong·
    SZ
    002581
    +1.89%

    ST Sinobioway Medicine: Tianjin Sinobioway is subject to other risk warnings

    ST Sinobioway Medicine announced that its controlling subsidiary, Tianjin Sinobioway Biomedical Co., Ltd., has been subjected to risk control measures that suspend production and sales, and it is expected that normal production and business activities cannot be resumed within three months. This triggers relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules." Starting from July 8, 2025, it will be subject to other risk warnings, and the stock abbreviation will be changed to "ST Sinobioway." The daily price fluctuation limit for stock trading will be 5%

    Zhitong·
    SZ
    002581
    +1.89%
    Zhitong·
    SZ
    002581
    +1.89%

    Sinobioway Medicine has been subjected to other risk warnings, and its stock abbreviation has been changed to "ST Sinobioway"

    Sinobioway Medicine's controlling subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., is expected to be unable to resume normal production. Starting from July 8, 2025, the stock will be subject to "other risk warnings," and its abbreviation will be changed to "ST Sinobioway." After a one-day suspension, it will resume trading with a daily price fluctuation limit reduced from 10% to 5%

    Zhitong·
    SZ
    002581
    +1.89%
    Zhitong·
    SZ
    002581
    +1.89%
    © 2025 Longbridge｜Disclaimer